Academic literature on the topic 'Antivirus Effectiveness'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antivirus Effectiveness.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Antivirus Effectiveness"
Prayitno, Lukman, Julien Rosye Mawuntu, Herna, and Tri Juni Angkasawati. "Review the Use of Antivirus for COVID-19 Treatment." Journal of Health Management 22, no. 4 (December 2020): 578–92. http://dx.doi.org/10.1177/0972063420983113.
Full textSukwong, Orathai, Hyong Kim, and James Hoe. "Commercial Antivirus Software Effectiveness: An Empirical Study." Computer 44, no. 3 (March 2011): 63–70. http://dx.doi.org/10.1109/mc.2010.187.
Full textThomas, Remya, and M. Nachamai. "Performance Investigation of Antivirus - A Comparative Analysis." Oriental journal of computer science and technology 10, no. 1 (March 24, 2017): 201–6. http://dx.doi.org/10.13005/ojcst/10.01.27.
Full textXu, Tie-Long, Yin Han, Wei Liu, Xing-Ya Pang, Bin Zheng, Yi Zhang, and Xiao-Nong Zhou. "Antivirus effectiveness of ivermectin on dengue virus type 2 in Aedes albopictus." PLOS Neglected Tropical Diseases 12, no. 11 (November 19, 2018): e0006934. http://dx.doi.org/10.1371/journal.pntd.0006934.
Full textPurkait, Swapan. "Examining the effectiveness of phishing filters against DNS based phishing attacks." Information & Computer Security 23, no. 3 (July 13, 2015): 333–46. http://dx.doi.org/10.1108/ics-02-2013-0009.
Full textO. E., Rubtsov, Norkina A. N., and Chicherov K.A. "Information Protection Tools for Android-based Mobile Devices." KnE Social Sciences 3, no. 2 (February 15, 2018): 235. http://dx.doi.org/10.18502/kss.v3i2.1548.
Full textAtmojo, Joko Tri, Rejo Rejo, Dewi Arradini, Aquartuti Tri Darmayanti, and Aris Widiyanto. "Pilihan Terapi Infeksi Covid-19 Pada Anak." Interest : Jurnal Ilmu Kesehatan 9, no. 2 (November 30, 2020): 201–11. http://dx.doi.org/10.37341/interest.v9i2.218.
Full textYao, Xueting, Zhe Hou, Cheng Cui, Miao Zhang, Siqi Tu, Haiyan Li, and Dongyang Liu. "Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population." Current Drug Metabolism 21, no. 7 (November 5, 2020): 534–40. http://dx.doi.org/10.2174/1389200221666200711160440.
Full textEvglevskaya, N. V., A. Yu Zuev, A. O. Karasenko, and O. S. Lauta. "Comparative analysis of the effectiveness of existing methods of networks security from DDoS attacks." Radio industry (Russia) 30, no. 3 (September 8, 2020): 67–74. http://dx.doi.org/10.21778/2413-9599-2020-30-3-67-74.
Full textSong, Lijuan, Cui Ma, Qiang Li, Aijun Fan, and Kaifa Wang. "Global dynamics of a viral infection model with full logistic terms and antivirus treatments." International Journal of Biomathematics 10, no. 01 (November 15, 2016): 1750012. http://dx.doi.org/10.1142/s1793524517500127.
Full textDissertations / Theses on the topic "Antivirus Effectiveness"
Leung, Yue-hin Ryan, and 梁宇軒. "Effectiveness of antiviral prophylaxis as a containment measure duringan influenza epidemic." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B48424079.
Full textpublished_or_final_version
Public Health
Master
Master of Public Health
Nagai, Kota. "Estimating the cost-effectiveness of screening for hepatitis C virus infection in Japan." Doctoral thesis, Kyoto University, 2021. http://hdl.handle.net/2433/263581.
Full textErsan, Erkan. "On the (in)security of behavioral-based dynamic anti-malware techniques." Thesis, 2017. http://hdl.handle.net/1828/7935.
Full textGraduate
2018-02-07
0984
erkanersan@gmail.com
Hsu, Yao-Chun, and 許耀峻. "Effectiveness of antiviral therapy for hepatitis C virus infection in extrahepatic outcomes." Thesis, 2015. http://ndltd.ncl.edu.tw/handle/88114005763842075581.
Full textWU, CHIN-CHEN, and 吳菁珍. "Assessment of Effectiveness and Health-Related Quality of Life Improvement in Chronic Hepatitis C Patients Treated with All Oral Direct Antiviral Agents." Thesis, 2019. http://ndltd.ncl.edu.tw/handle/5frbxh.
Full text長榮大學
醫務管理學系碩士班
107
Purpose The World Hepatitis Summit was convened by World Health Organization (WHO) at Glasgow, Scotland, in September of 2015, and has proposed that hepatitis C would be eliminated by 2030. In 2017, the National Health Insurance Administration (NHIA) of MOHW approved to allocate a budget for hepatitis C medication to cover all-oral antiviral drugs. The purpose of this study was to investigate the effectiveness of all-oral antiviral drugs and quality of life. Method This study was conducted as a cross-sectional study to investigate patients who were covered by this health insurance plan for oral drug treatment for Chronic hepatitis C (CHC) from 2017 to 2018. Two instruments (a generic and a specific one) were used to measure the quality of life, World Health Organization Quality of Life (WHOQOL-BREF) statistics and Chronic Liver Disease Questionnaire (CLDQ). Data collections are from medical records and Virtual Private Network (VPN) of NHIA. The Statistical Package for the Social Science (SPSS) was used to analyze the results with descriptive statistics, t-test, ANOVA, and multiple regression analysis, etc. Results The efficacy of all-oral antiviral drugs treatment reached up to 97%, which is higher than the traditional interferon based therapy. The results showed better improvement in clinical value like GOT, GPT, alpha fetoprotein, direct bilirubin, and international normalized ratio (INR). There were no significant treatment effect differences in the regiments between sofo and non-sofo (p>0.05). With convenience sampling, we recruited 50 patients who were treated with DAA, and reached SVR12 to survey their quality of life. The results showed that: (1) After the DAA treatment, they got improvement in their quality of life (p<0.05); (2) There were no differences in quality of life with different drug regimens or levels of liver cirrhosis (p>0.05); (3) The CHC patients with a job got high quality of life in four domains: Physical health, Psychological, Social relationships, and Environment from the WHOQOL-BREF statistics (p>0.05); (4) The CHC patients with a job got high quality of life in four domains: Fatigue, Emotional Health, Systemic Symptoms and Activity from the CLDQ. (p>0.05); (5) Age, marital status, education, occupation, and income were important predictors of quality of life in multiple regression analyses. Conclusion There are no significant differences in treatment effects with all-oral antiviral regimens (sofo vs. non-sofo medication therapy), and CHC patients get improvements in their quality of life after the treatment. Due to different demographics, CHC patients may have negative impact on Psychological, Emotional Health, and Activity during DAA therapy. Therefore, case managers shall provide psychological support to improve the medication adherence, and to complete the treatments and follow-up.
"Clinical management of influenza-like illness in the outpatient setting: Assessing the joint cost effectiveness of influenza point-of-care testing practices and antiviral treatment." Tulane University, 2020.
Find full textBackground: Prompt antiviral treatment of influenza virus infections can improve outcomes and reduce the likelihood of complications, particularly among children at high risk for complications. Recent, more stringent requirements for rapid influenza point-of-care test clinical sensitivity have implications for the impact and cost-effectiveness of outpatient influenza diagnosis and antiviral treatment. Objective: The objective of this research was to understand antiviral prescribing practices following and utilize these real-world probabilities to evaluate the cost effectiveness of rapid test-guided outpatient antiviral treatment in children. Methods: The analysis used data from patients presenting for outpatient care with influenza-like illness (ILI) collected through the Influenza Incidence and Surveillance Project (IISP). The first analysis used a retrospective case-control design to compare clinic, patient, and season characteristics that influenced the decision to prescribe influenza antiviral treatment following a negative rapid influenza detection test. The IISP data were then incorporated into cost-effectiveness analyses among high-risk and otherwise healthy children presenting for outpatient care with ILI. Results: The results from the first analysis demonstrated that clinicians prescribed influenza antivirals to 8.4% of all test-negative patients and that in age groups considered a proxy for high risk patients, prescribing was either less frequent among children aged <2 (aOR 0.4, 95% CI 0.3–0.6) or the same among adults aged ≥65 (aOR 0.9, 95% CI 0.7–1.3) compared with adults aged 18 to 64. The results from the antiviral cost-effectiveness analysis among healthy children showed that treatment guided by clinician judgement was cost saving compared to no treatment, but rapid testing produced the greatest benefit. Among high-risk children, test-guided treatment produced the greatest benefit and was cost effective. Results were sensitive to clinician diagnostic sensitivity, influenza prevalence and the probability a positive test or diagnosis would result in treatment. Conclusion: These studies indicated that clinical judgement continued to be used to prescribe antivirals for patients with suspected influenza, greatly impacting the associated costs of care. The decision to test for influenza should be contingent upon the results influencing treatment of the patient or high-risk contacts, or further costly diagnostic testing.
1
Ashley Fowlkes
Chikoka, Tariro. "Determinants of excellent and poor adherence to antiretroviral therapy in Barberton." Diss., 2015. http://hdl.handle.net/10500/21174.
Full textHealth Studies
M.P.H.
Books on the topic "Antivirus Effectiveness"
Institute of Medicine (U.S.). Board on Population Health and Public Health Practice., ed. Antivirals for pandemic influenza: Guidance on developing a distribution and dispensing program. Washington, DC: National Academies Press, 2008.
Find full textHusereau, Donald Robert. Oseltamivir for the treatment of suspected influenza: A clinical and economic assessment. Ottawa, Ont: Canadian Coordinating Office for Health Technology Assessment, 2001.
Find full textBrady, Bruce. Economic evaluation of Zanamivir for the treatment of influenza. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2001.
Find full textConference papers on the topic "Antivirus Effectiveness"
Haffejee, Jameel, and Barry Irwin. "Testing antivirus engines to determine their effectiveness as a security layer." In 2014 Information Security for South Africa (ISSA). IEEE, 2014. http://dx.doi.org/10.1109/issa.2014.6950496.
Full textAftaeva, L. N., V. L. Melnikov, E. A. Duvanova, A. A. Igoshina, and A. V. Danin. "The effectiveness of antiviral therapy for chronic hepatitis B." In Научный диалог: Вопросы медицины. ЦНК МОАН, 2018. http://dx.doi.org/10.18411/spc-15-06-2018-01.
Full textMarín, L. Martínez Dueñas López, E. González González, AManzano Bonilla, ACaballero Romero, EGalindo Sacristán, FMalpica Chica, and MCamacho Romera. "4CPS-228 Effectiveness and security of new direct-acting antiviral agents for hcv." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.318.
Full textZegarra Mondragon, S., J. R. Quiñones, J. Bachiller Corral, and M. Vazquez Diaz. "FRI0515 Effectiveness of direct-acting antiviral therapy on cryoglobulinemia associated with hepatitis c virus." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.6169.
Full textMargusino-Framiñan, L., C. Mondelo-Garcia, V. Gimenez-Arufe, N. Fernandez-Bargiela, C. Fernandez-Oliveira, S. Rotea-Salvo, P. Cid-Silva, et al. "5PSQ-040 Real-life direct-acting antivirals effectiveness comparative study in HIV-hepatitis C virus coinfected patients." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.473.
Full textSuprunova, T. P., N. V. Markin, A. N. Ignatov, A. G. Solovyov, N. O. Kalinina, and M. E. Talyansky. "Use of dsRNA-based antiviral compounds to protect potato plants." In Растениеводство и луговодство. Тимирязевская сельскохозяйственная академия, 2020. http://dx.doi.org/10.26897/978-5-9675-1762-4-2020-132.
Full textBiliavska, Liubov, Liubov Zelena, Nadiya Nesterova, Olga Povnitsa, Sergei Voychuk, Svitlana Zagorodnya, and Yulia Pankivska. "Study of Peculiarities of Viruses’ Interactions and Effectiveness of Antiviral Drugs in the Model of Mixed Infection." In 1st International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2015. http://dx.doi.org/10.3390/ecmc-1-a046.
Full textDewi, Beti Ernawati, Edianti Ratningpoeti, Hidayati Desti, and Marissa Angelina. "In vitro and in silico study to evaluate the effectiveness of quercitrin as antiviral drug to dengue virus." In THE 4TH BIOMEDICAL ENGINEERING’S RECENT PROGRESS IN BIOMATERIALS, DRUGS DEVELOPMENT, HEALTH, AND MEDICAL DEVICES: Proceedings of the International Symposium of Biomedical Engineering (ISBE) 2019. AIP Publishing, 2019. http://dx.doi.org/10.1063/1.5139341.
Full textVicente, MC Serrano, A. Escolano Pueyo, MC Viñuales Armengol, N. Allué Fantova, L. Torres Sopena, and MP Amador Rodríguez. "CP-126 Effectiveness and safety assessment of direct acting antiviral in the treatment of chronic hepatitis C virus infection." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.125.
Full textMolina, M., F. Moreno, I. Jimenez, A. Gonzalez, C. Jimenez, A. Rossignoli, M. Freire, and A. Herrero. "CP-064 Effectiveness of new direct acting antivirals for chronic hepatitis C depending on genotype in real medical practice." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.63.
Full text